Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force "Dermatology for Cancer Patients" International Study.
Pietro SollenaVasiliki A NikolaouElias KotteasAlexander J StratigosDavide FattoreArmando OrlandiMaria ManninoMarcello Di PumpoMonika FidaMichela Valeria Rita StaraceZoe ApallaMaria Concetta RomanoJulia RigantiSonia SeguraAzael Freites MartinezGabriella FabbrociniVincent SibaudKetty Perisnull On Behalf Of The Eadv Task Force Dermatology For Cancer PatientsPublished in: Cancers (2023)
To the best of our knowledge, we present the largest case series of cutaneous adverse events developing in advanced breast cancer patients treated with CDK4/6i. We showed that cutaneous toxicities are usually mild in severity, and manageable with standard supportive care; however, in selected cases, they can lead to treatment discontinuation with possible implications for patients' clinical outcomes.